IDEAYA Biosciences, Inc. IDYA
Set alert
31.64 USD -0.32 -1.00%
At close · Nov 2
31.64 0.00 0.00%
After hours · Nov 2, 4:00 PM ET
31.10 Day range 32.42
26.81 52-week range 42.68
- YTD
- -8.48%
- 1 year
- -0.69%
- Open
- 32.14
- Prev close
- 31.96
- Mkt cap
- 3.05B
- Vol
- 789.94K
- Avg vol
- 818.03K
- EPS
- -1.94
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 31.10
- High
- 32.42
- Forward P/E
- -7.69
- Beta
- 0.08
- Short ratio
- 9.87
- Inst. own
- 107.62%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 9, 2026
- 50-d avg
- 37.24
- 200-d avg
- 34.02
- 1y target
- 51.92
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 51.92 +64.1% upside
Now 31.64
- Target (low)
- 31.00
- Target (mean)
- 51.92
- Target (high)
- 65.00
Ratings (0m) 16 15 buy · 1 hold · 0 sell
- Strong buy3
- Buy12
- Hold1
- Sell0
- Strong sell0
Recommendation trend
- This month 16
- 1 month ago 14
- 2 months ago 15
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -1.16 | -1.42 – -0.84 | 1.33 | -187.5% | 7.58M | -96.3% | 14 |
| Next quarter | -1.14 | -1.44 – -0.82 | -0.94 | -20.9% | 19.72M | +81.3% | 14 |
| Current year | -4.59 | -5.20 – -4.02 | -1.28 | -258.4% | 41.01M | -81.3% | 14 |
| Next year | -4.11 | -5.43 – -1.78 | -4.59 | +10.3% | 118.30M | +188.5% | 13 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 16, 2026 | William Blair | Initiated | — | Outperform |
| Oct 14, 2026 | Stifel | Initiated | — | Buy |
| Sep 9, 2026 | Guggenheim | Maintained | Buy | Buy |
| Sep 1, 2026 | Citizens | Reiterated | Market Outperform | Market Outperform |
| Aug 5, 2026 | Truist Securities | Maintained | Buy | Buy |
| Aug 5, 2026 | Wedbush | Maintained | Outperform | Outperform |
| Jul 7, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| Jul 7, 2026 | Truist Securities | Maintained | Buy | Buy |
| Jun 12, 2026 | Wedbush | Reiterated | Outperform | Outperform |
| Jun 2, 2026 | Wedbush | Reiterated | Outperform | Outperform |
| May 7, 2026 | Mizuho | Maintained | Outperform | Outperform |
| Apr 14, 2026 | Goldman Sachs | Maintained | Neutral | Neutral |
| Apr 14, 2026 | Wells Fargo | Maintained | Overweight | Overweight |
| Apr 14, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| Apr 14, 2026 | Wedbush | Maintained | Outperform | Outperform |
| Apr 14, 2026 | Guggenheim | Maintained | Buy | Buy |
| Mar 31, 2026 | Wedbush | Reiterated | Outperform | Outperform |
| Feb 19, 2026 | Citigroup | Maintained | Buy | Buy |
| Feb 18, 2026 | RBC Capital | Reiterated | Outperform | Outperform |
| Feb 18, 2026 | Guggenheim | Reiterated | Buy | Buy |
| Feb 18, 2026 | Wedbush | Maintained | Outperform | Outperform |
| Jan 21, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| Jan 6, 2026 | Truist Securities | Maintained | Buy | Buy |
| Nov 24, 2025 | Truist Securities | Initiated | — | Buy |
| Nov 11, 2025 | Mizuho | Maintained | Outperform | Outperform |
| Oct 23, 2025 | JP Morgan | Maintained | Overweight | Overweight |
| Oct 21, 2025 | Goldman Sachs | Maintained | Neutral | Neutral |
| Oct 21, 2025 | RBC Capital | Maintained | Outperform | Outperform |
| Oct 21, 2025 | BTIG | Reiterated | Buy | Buy |
| Sep 18, 2025 | Guggenheim | Initiated | — | Buy |